A detailed history of Neuberger Berman Group LLC transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, Neuberger Berman Group LLC holds 87,270 shares of ITCI stock, worth $7.54 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
87,270
Previous 96,314 9.39%
Holding current value
$7.54 Million
Previous $6.6 Million 3.26%
% of portfolio
0.01%
Previous 0.01%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$67.99 - $80.84 $614,901 - $731,116
-9,044 Reduced 9.39%
87,270 $6.38 Million
Q2 2024

Nov 14, 2024

BUY
$64.76 - $79.84 $938,890 - $1.16 Million
14,498 Added 17.72%
96,314 $6.6 Million
Q2 2024

Aug 13, 2024

BUY
$64.76 - $79.84 $938,890 - $1.16 Million
14,498 Added 17.72%
96,314 $6.6 Million
Q1 2024

Nov 14, 2024

BUY
$64.37 - $75.65 $1.67 Million - $1.96 Million
25,965 Added 46.49%
81,816 $5.66 Million
Q1 2024

May 13, 2024

BUY
$64.37 - $75.65 $5.27 Million - $6.19 Million
81,816 New
81,816 $5.66 Million
Q4 2023

Nov 14, 2024

SELL
$46.37 - $73.65 $1.88 Million - $2.98 Million
-40,463 Reduced 42.01%
55,851 $4 Million
Q4 2023

Feb 09, 2024

BUY
$46.37 - $73.65 $2.3 Million - $3.65 Million
49,607 Added 794.47%
55,851 $4 Million
Q3 2023

Nov 14, 2023

BUY
$52.09 - $64.1 $19,690 - $24,229
378 Added 6.44%
6,244 $325,000
Q2 2023

Aug 11, 2023

BUY
$54.67 - $66.44 $24,820 - $30,163
454 Added 8.39%
5,866 $371,000
Q1 2023

May 12, 2023

BUY
$43.8 - $56.99 $50,457 - $65,652
1,152 Added 27.04%
5,412 $293,000
Q4 2022

Feb 13, 2023

BUY
$44.07 - $54.45 $187,738 - $231,957
4,260 New
4,260 $225,000

Others Institutions Holding ITCI

About Intra-Cellular Therapies, Inc.


  • Ticker ITCI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 94,401,696
  • Market Cap $8.16B
  • Description
  • Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...
More about ITCI
Track This Portfolio

Track Neuberger Berman Group LLC Portfolio

Follow Neuberger Berman Group LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Neuberger Berman Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Neuberger Berman Group LLC with notifications on news.